News

Arvinas to Present at Jefferies Global Healthcare Conference

NEW HAVEN, Conn., May 30, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop…

7 months ago

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology…

7 months ago

Ascend Aesthetic Partners Welcomes David Cutter as COO

David Cutter Ascend Aesthetic Partners COO ATLANTA, May 30, 2025 (GLOBE NEWSWIRE) -- Ascend Aesthetic Partners (Ascend) is pleased to…

7 months ago

Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference

DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil"), a clinical-stage biopharmaceutical company focused on developing…

7 months ago

Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series

Featuring top researchers and industry experts using high-throughput proteomics to drive breakthroughs in population health, translational research and clinical developmentSOUTH…

7 months ago

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval…

7 months ago

Immuron Letter to Shareholders: Projects Update

Highlights: Immuron on track to exceed A$7 million in Sales this financial yearUniformed Services University anticipates topline results of Travelan®…

7 months ago

EssilorLuxottica to acquire Optegra clinics, another leap forward in its med-tech strategy

EssilorLuxottica to acquire Optegra clinics,another leap forward in its med-tech strategy Acquisition of leading ophthalmology platform from MidEuropa will advance…

7 months ago

Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless…

7 months ago